364793-91-9

Basic information

• Product Name: 4-((5-bromopyridin-3-yl)methyl) morpholine
• Synonyms: 4-((5-bromopyridin-3-yl)methyl) morpholine
• CAS NO: 364793-91-9
• Molecular Formula: C10H13BrN2O
• Molecular Weight: 257
• Mol File: 364793-91-9.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-((5-bromopyridin-3-yl)methyl) morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((5-bromopyridin-3-yl)methyl) morpholine(364793-91-9)
• EPA Substance Registry System: 4-((5-bromopyridin-3-yl)methyl) morpholine(364793-91-9)

Safety Data

• Hazardous Substances Data: 364793-91-9(Hazardous Substances Data)

Usage

General Description

4-((5-bromopyridin-3-yl)methyl)morpholine is a chemical compound that has the molecular formula C10H13BrN2O. This chemical belongs to the class of organic compounds known as morpholines, which are heterocyclic compounds containing a morpholine ring, which is a six-member ring with four carbon atoms, one oxygen atom and one nitrogen atom. The presence of the bromopyridin-3-yl group indicates that it also contains a bromine atom and a pyridine ring. This chemical compound is used predominantly as a reagent in the synthesis of other chemical compounds. It does not exist in a natural form and is synthesized in the laboratory for use in various applications. Like all chemicals, it should be handled with care, as it might be hazardous if improperly used.

Upstream product

• 342013-81-4 4-[(5-bromopyridin-3-yl)carbonyl]morpholine 
• 110-91-8 morpholine 
• 39741-46-3 3-bromo-5-(chloromethyl)-pyridine hydrochloride 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 

Downstream Products

• 919347-16-3 4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine 

Relevant articles and documents

PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY

Pyrazole compounds (I) for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a pyrazole compounds, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS

FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.